Boží mlýny

MUDr. Richard Krombholz

Interní Med. 2013; 15(10): 287  

Heart failure in the light of the new CSC and ESC guidelines

prof.MUDr.Jiří Vítovec, CSc., FESC, prof.MUDr.Jindřich Špinar, CSc., FESC

Interní Med. 2013; 15(10): 289-291  

The authors present differences in the guidelines for diagnosis and treatment of heart failure of the European Society of Cardiology (ESC) and the Czech Society of Cardiology (CSC).

Linagliptin in the treatment of type 2 diabetes mellitus current status and perspectives

prof.MUDr.Martin Haluzík, DrSc., MUDr.Pavel Trachta

Interní Med. 2013; 15(10): 292-297  

Increased prevalence of type 2 diabetes and its complications worldwide emphasizes the importance of its novel treatment options. While metformin is clearly considered a first-choice treatment optimal add-on medication to metformin is still intensively discussed. The group of dipeptidyl peptidase-4 inhibitors (DPP-4) represents a very promising option with good efficacy and low risk of side effect that are commonly present with the use of traditional sulphonylureas. Linagliptin is one of the representatives of DPP-4 inhibitors differing from other members of this group by unique pharmacokinetics. This feature enables its administration to not...

Actual possibilities of modern anticoagulant therapy

MUDr.Zdeněk Coufal

Interní Med. 2013; 15(10): 298-300  

New antikoagulant agents (dabigatran, rivaroxaban and apixaban) give significantly higher possibilities in trombembolic prevention in patients with nonvaluvular atrial fibrillation with same or higher efficiency and same or lower bleeding risk in comparison with dose adjusted warfarin. New anticoagulants have advantage especially in pacients with poor warfarin treatment control and/or higher bleeding risk.

Pharmacotherapy and non-pharmacological treatment of obesity

MUDr.Klára Owen, Ph.D.

Interní Med. 2013; 15(10): 302-304  

The increased number of obese patients, and the increasing degree of obesity in them neccessitates better awarenes of therapeutic options by doctors of all specialities. Presented article summarises current approach to treating obesity, starting with lifestyle modificiations, ie. change in diet and improvement in exercise patterns, discusses pharmacotherapeutic modalities, either registered in the Czech republic, or imported individually, and concludes with a brief summary of surgical treatments in form of bariatric surgery.

Present-day therapy of varicose veins

doc.MUDr Jiří Herman, Ph.D.

Interní Med. 2013; 15(10): 305-309  

Article deals with therapy of varicose veins. Mentions surgery, conservative treatment, compression therapy and compresive sclerotisation. This methods of therapy matches with particular condition.

Eruptive xanthomatosis as first manifestation of diabetes mellitus

doc.MUDr.David Karásek, Ph.D., prof.MUDr.Helena Vaverková, CSc., Ing.Dalibor Novotný, Ph.D.

Interní Med. 2013; 15(10): 314-317  

The authors describe a patient who displayed eruptive xanthomatosis as a manifestation of severe mixed dyslipidemia. Type 2 diabetes mellitus was newly diagnosed in the patient. In addition to insulin resistance in abdominal obesity and an excessive fat intake the genetic predisposition probably contributed to the development of dyslipidemia too. The patient was identified as a carrier for ε4 allele of the gene for apolipoprotein E. Treatment of dyslipidemia and diabetes led to metabolic compensation and complete regression of skin lesions.

Combined dyslipidaemia secondary to severe hypothyreosis

MUDr.Ľubica Cibičková, Ph.D., doc.MUDr.David Karásek, Ph.D.

Interní Med. 2013; 15(10): 318-320  

We describe a case of a young man, who presented with combined dyslipidaemia with predominant elevation of total and LDL cholesterol. Severe thyroid hypofunction due to long undiagnosed Hashimoto thyroiditis was found to be the underlying cause. The lipid parameters gradually improved in response to substitution. This case report underlines the importance of excluding hypothyroidism as the most common aetiology of secondary dyslipidaemia.

Genetics of anxiety disorders

prof.MUDr.Ladislav Hosák, Ph.D., MUDr.Petr Šilhán, Mgr.Jiřina Hosáková

Interní Med. 2013; 15(10): 311-313  

Heritability of anxiety disorders is the least of all psychiatric diseases – only 20 to 40 %. Environmental factors, especially the psychotraumatizing ones, are deciding. Although series of genetic association studies in anxiety disorders have already been performed, their results are typically negative, inconsistent, or non-replicated. On the present day, practically no gene can be considered as a causative one in the etiopathogenesis of anxiety disorders. A basically new knowledge can be attained by whole-genome association studies and genetic analyses of endophenotypes in the future. It will be useful in our finding of modern biological...

Stanovisko výboru ČSAT k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2011

prof.MUDr.Vladimír Soška, CSc., prof.MUDr.Helena Vaverková, CSc., doc.MUDr.Michal Vrablík, Ph.D., prof.MUDr.Vladimír Bláha, CSc., prof.MUDr.Renata Cífková, CSc., MUDr.Tomáš Freiberger, CSc., doc.MUDr.Pavel Kraml, CSc., MUDr.Jan Piťha, CSc., prof.MUDr.Hana Rosolová, DrSc., doc.MUDr.Tomáš Štulc, Ph.D., doc.MUDr.Zuzana Urbanová, CSc.

Interní Med. 2013; 15(10): 322-326  

Některé léky a změny úseku S-T

doc.MUDr.Čestmír Číhalík, CSc.

Interní Med. 2013; 15(10): 320-321